A view of the logo of Novo Nordisk at the company’s office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024.
Tom Little | Reuters
Shares of Novo Nordisk jumped Friday after the Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
The trial showed average weight reduction of 22% in obese and overweight patients after 36 weeks.
Shares were last up 9.5% at 11:02 a.m. London time.
This is a developing story. Please check back for updates.
